STOCK TITAN

Amphastar Pharma - AMPH STOCK NEWS

Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.

Overview

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a specialty bio-pharmaceutical company renowned for its expertise in developing, manufacturing, marketing, and selling technically challenging injectable, inhalation, and intranasal pharmaceutical products. With operations centered in the United States and an established international presence, Amphastar has built a reputation for leveraging state-of-the-art, cGMP compliant facilities to meet high industry standards and regulatory requirements.

Operational Excellence

Operating multiple cutting-edge manufacturing facilities across the United States, China, and Europe, Amphastar demonstrates a robust global operational strategy. The company’s facilities adhere strictly to current Good Manufacturing Practices (cGMP), ensuring that every product meets the rigorous quality benchmarks mandated in the pharmaceutical industry. This commitment to operational excellence is further emphasized by its integrated research centers dedicated to the development of both generic and proprietary products.

Product Portfolio and Innovation

Amphastar’s diverse portfolio includes a wide range of products, from injectable drugs to inhalation and intranasal therapies, as well as insulin Active Pharmaceutical Ingredient (API) products. The company’s expertise in formulating complex drug products is reflected in its ability to manufacture products that are used primarily in hospital and urgent care clinical settings. Its portfolio is designed to target high-technical barrier market opportunities, ensuring that the products address critical therapeutic needs while satisfying strict regulatory standards.

Manufacturing and Quality Commitment

At the heart of Amphastar’s operations is a commitment to quality and innovation. The company’s facilities are equipped with advanced technology to support precise and efficient manufacturing processes. By maintaining cGMP compliance across its manufacturing sites, Amphastar is able to consistently deliver products that meet both domestic and international quality standards. This operational discipline underpins the company’s ability to secure substantial market share upon product launch.

Market Position and Distribution

Amphastar is strategically positioned within the pharmaceutical market through longstanding relationships with group purchasing organizations and drug wholesalers. This network not only enhances distribution capabilities but also solidifies the company’s market presence, particularly within the U.S. healthcare system. The systematic distribution through these channels ensures that its innovative products reach clinical settings where they are needed most.

Research and Development

The company’s dedicated research and development efforts are driven by a focus on both generic and proprietary products. Amphastar continually invests in R&D to refine its product formulations and expand its product pipeline. By filing abbreviated new drug applications (ANDAs) and developing biosimilars alongside proprietary drugs formulated in injectable and intranasal dosage forms, the company blends innovation with market demand. This adaptive approach reflects its ability to meet evolving therapeutic needs while maintaining regulatory compliance.

Industry Expertise and Strategic Approach

Amphastar’s deep-rooted expertise in pharmaceutical manufacturing is evident through its reliable production processes, adherence to quality standards, and commitment to continuous improvement. The company leverages its technical expertise and advanced manufacturing infrastructure to navigate a highly competitive environment. Its focus on technically challenging products positions it in a unique niche within the broader pharmaceutical industry, where every innovation is underpinned by robust scientific research and quality control.

Investor Focus and Competitive Landscape

For investors, analyzing Amphastar means understanding a company that skillfully balances high-quality manufacturing with strategic market positioning. The company's integrated approach to production and distribution, combined with its expertise in complex pharmaceutical formulations, provides a framework for evaluating its competitive standing. By focusing on well-established market channels and continuously evolving its product portfolio, Amphastar demonstrates a disciplined operational model that is built on quality assurance and technical proficiency.

Conclusion

This comprehensive overview of Amphastar Pharmaceuticals presents an in-depth examination of its operations and strategic positioning. The company’s commitment to quality, innovation, and regulatory compliance forms the backbone of its competitive edge. With advanced manufacturing facilities and a diverse product array, Amphastar continues to serve critical needs within the healthcare industry, offering insights for analysts and investors seeking a detailed understanding of its business model.

Rhea-AI Summary

Amphastar Pharmaceuticals announced that the FDA has tentatively approved its ANDA for Vasopressin injection, a critical drug indicated for increasing blood pressure in adults with vasodilatory shock. The market for VASOSTRICT®, the branded equivalent, was approximately $856 million in U.S. sales as of September 30, 2021. Amphastar plans to manufacture its product in the U.S. The company has several additional products in its pipeline, targeting a combined market size of over $28 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) participated in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021. Key executives, including CFO Bill Peters and V.P. of Corporate Communications Dan Dischner, engaged in an analyst-moderated fireside chat. The presentation will be available on Amphastar's website starting the same day at 10:00 AM EST and will remain accessible for 90 days. Amphastar focuses on developing and marketing injectable and inhalation products used in clinical settings. For more details, visit ir.amphastar.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced participation in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on November 18, 2021. Key executives, including Bill Peters and Dan Dischner, will present a pre-recorded session available at 8:00 am GMT. The event will be accessible for 90 days via the company's website. Amphastar specializes in developing and manufacturing generic and proprietary injectable and inhalation products, primarily for hospital and urgent care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported a strong financial performance for Q3 2021, with net revenues reaching $112.2 million, up 34% from $83.4 million in Q3 2020. The GAAP net income was $29.5 million, or $0.59 per share. Key product drivers included Primatene Mist, epinephrine, and glucagon, showing substantial sales increases. The company also highlighted a robust pipeline with several products aimed at a combined market size exceeding $27 billion. The significant gain from the restructuring of its Chinese subsidiary contributed to non-operating income growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its third-quarter 2021 results on November 8, 2021, after market close. The company will host a conference call at 2:00 p.m. PT to discuss the financial outcomes. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital use. The call can be accessed via telephone or through the company’s investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 2:00 PM ET. Key executives including CFO Bill Peters and Sr. VP Tony Marrs will participate in the presentation. A webcast will be available for viewing on Amphastar's website for 90 days post-event. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for clinical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
Rhea-AI Summary

Amphastar Pharmaceuticals reported net revenues of $101.7 million for Q2 2021, an 18% increase from the previous year. The company achieved a GAAP net income of $7.8 million ($0.16 per share) and an adjusted non-GAAP net income of $10.6 million ($0.21 per share). Key growth drivers included strong sales of Primatene Mist, glucagon, and epinephrine. The company also announced plans to increase its share buyback program by $20 million and refinanced $30 million of debt, enhancing financial flexibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its second quarter 2021 results on August 9, 2021, after market close. A conference call is scheduled for 2:00 PM Pacific Time to discuss these results. The company specializes in developing, manufacturing, and marketing generic and proprietary injectable and inhalation products mainly used in clinical settings. The conference call can be accessed by dialing (877) 407-0989 for domestic calls or (201) 389-0921 for international calls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that key executives will present at the Human Health Innovation Conference on June 22, 2021, at 2:00 PM Eastern Time. The panel includes Bill Peters (CFO), Dan Dischner (VP of Corporate Communications), Tony Marrs (SVP of Regulatory Affairs), and Jacob Liawatidewi (EVP of Corporate Administration). A webcast of the presentation will be accessible on Amphastar's website for 90 days following the event. Amphastar focuses on developing and marketing challenging generic and proprietary injectable products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences
Rhea-AI Summary

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:30 pm Eastern Time. Key executives, including CFO Bill Peters and VP Dan Dischner, will be present. The event will be webcast and available for 90 days on Amphastar's website. Amphastar specializes in developing and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences

FAQ

What is the current stock price of Amphastar Pharma (AMPH)?

The current stock price of Amphastar Pharma (AMPH) is $26.61 as of April 4, 2025.

What is the market cap of Amphastar Pharma (AMPH)?

The market cap of Amphastar Pharma (AMPH) is approximately 1.3B.

What is Amphastar Pharmaceuticals' core business?

Amphastar specializes in developing, manufacturing, marketing, and selling technically challenging generic and proprietary pharmaceutical products, including injectable, inhalation, and intranasal formulations.

What types of products does Amphastar produce?

The company produces a range of products such as injectable drugs, inhalation and intranasal therapies, and insulin Active Pharmaceutical Ingredient (API) products, primarily used in clinical settings.

How do Amphastar's manufacturing facilities support its operations?

Amphastar operates multiple state-of-the-art, cGMP compliant facilities across the United States, China, and Europe, ensuring high-quality production and adherence to strict regulatory standards.

What role does research and development play at Amphastar?

R&D is central to Amphastar's operations. The company continually invests in developing both generic and proprietary products, enhancing its product pipeline and addressing high technical barriers in the pharmaceuticals market.

How does Amphastar distribute its products?

The company utilizes established relationships with group purchasing organizations and drug wholesalers to efficiently distribute its products, primarily across hospital and urgent care settings.

What distinguishes Amphastar in the competitive pharmaceutical landscape?

Amphastar stands out due to its integrated approach combining advanced manufacturing, rigorous quality control, and a diversified product portfolio tailored to meet high-demand therapeutic needs.

Can you explain the significance of cGMP compliance for Amphastar?

cGMP compliance ensures that Amphastar’s manufacturing processes meet the highest quality and safety standards, supporting reliable product performance and regulatory approval both domestically and internationally.

How does Amphastar manage regulatory challenges?

Amphastar maintains strict adherence to regulatory guidelines through state-of-the-art facilities and a dedicated R&D focus, ensuring all products are manufactured according to current Good Manufacturing Practices and relevant international standards.
Amphastar Pharma

Nasdaq:AMPH

AMPH Rankings

AMPH Stock Data

1.27B
36.73M
22.56%
76.09%
8.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
RANCHO CUCAMONGA